Synthesis, oral bioavailability evaluation and antiplatelet aggregation activity of three derivatives of 3,4‑dihydroxyacetophenone

Sun,Na; Qu,Mei; Wang,Mengyu; Lv,Yanna; Wei,Liuya; Duan,Yu

doi:10.3892/ijmm.2020.4469

Synthesis, oral bioavailability evaluation and antiplatelet aggregation activity of three derivatives of 3,4‑dihydroxyacetophenone

Authors:
- Na Sun
- Mei Qu
- Mengyu Wang
- Yanna Lv
- Liuya Wei
- Yu Duan
View Affiliations

Affiliations: School of Pharmacy, Weifang Medical College, Weifang, Shandong 261053, P.R. China
Published online on: January 20, 2020 https://doi.org/10.3892/ijmm.2020.4469
Pages: 919-930

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

3,4‑Dihydroxyacetophenone (DHAP) exerts therapeutic effects on cardiovascular disease and pulmonary heart disease. However, it is not utilized as a clinical drug due to its rapid metabolism, short‑acting effect and low oral bioavailability. In the present study, three derivatives of DHAP, including 4‑acetyl‑1,2‑phenylene dipropionate (APDP), 1‑(3‑hydroxy‑4‑phenoxy‑phenyl)‑ethanone (HPPE) and a polymer derivative, PEG‑DHAP, were synthesized via the esterification or etherification of hydroxyls at C3 and C4, which are the prime metabolism sites of DHAP. The physicochemical properties, pharmacokinetic and antiplatelet aggregation activities of these derivatives were measured to determine whether they can improve the defects of DHAP. The results revealed that APDP and HPPE exhibited markedly lower water solubility and higher oil‑water partition coefficients compared to DHAP. APDP rapidly transformed into DHAP in vivo and in vitro, indicating that there were no significant differences in the values of mean residence time in vivo [MRT (0‑t)], half‑life [t1/2], oral bioavailability and antiplatelet aggregation activity in vivo and in vitro between the two agents. HPPE partially released DHAP for a period of time following oral administration. PEG‑DHAP contained 12.47% DHAP dispersed into nanoparticles with a mean particle size of 260.90 nm. This was administered in aqueous solution and was demonstrated to release DHAP slowly following oral administration. These two derivatives significantly prolonged the in vivo acting time and increased the oral bioavailability of DHAP: Following intragastric administration, their MRT (0‑t) and t1/2 values were 3.55‑11.47‑ and 6.63‑11.25‑fold higher compared with those of DHAP, respectively. Additionally, their relative bioavailability was 394.79 and 331.88%, respectively, and they exhibited longer acting times of significant antiplatelet aggregation activity. The results of the present study may thus provide a reference for the development of DHAP as an oral drug. Furthermore, the results if this study may prove to be useful to researchers addressing the issue of the poor bioavailability of phenolic drugs.

View Figures

View References

1	Beijing Pharmaceutical Industry Research Institute, Chinese People's Liberation Army 157 Hospital: Study on the active constituents of leaves of Ilex pubescens Hook et Arn var glaber Chang. Chin Trad and Herb Drugs Commun. 8:7–10. 1977.In Chinese.
2	Research Group of the Therapeutic Effects of Qingxintong: Summary of the treatment effects of Qingxintong on angina pectoris of coronary heart disease. Beijing Pharm Industry. 1:23–27. 1983.In Chinese.
3	Chinese People's Liberation Army 157 Hospital: Clinical observation of 50 cases of coronary heart disease treated with Qingxintong injection. Beijing Pharm Industry. 1:27–29. 1983.In Chinese.
4	Beijing pharmaceutical industry research institute: Effect of Qingxintong on thrombosis in patients with coronary heart disease. Beijing Pharm Industry. 1:16–17. 1983.In Chinese.
5	Beijing Pharmaceutical Research Institute: Research on the pharmacologic effect of leaves of Qingxintong on coronary heart disease. Chin Trad and Herb Drugs. 11:358–366. 1980.In Chinese.
6	Lin CL, Zhang ZX and Xu YJ: Therapeutic mechanism of qingxintong on chronic obstructive pulmonary disease. Chin J Tuberculosis and Respirat. 18:97–98. 1995.In Chinese.
7	Lin CL, Zhang ZX, Xu YJ and Ni W: Effects of qingxintong on hemodynamics and atrial natriuretic peptide and cyclic glucosides in patients with chronic obstructive pulmonary disease. Chin J Integrated Trad Chin Western Med. 15:131–133. 1995.In Chinese.
8	Lin CL, Zhang ZX and Xu YJ: Effects of 3.4-dihydroxyaceto-phenine on hemorheology and plasma levels of TXA2, CD62P in patients with chronic pulmonary heart disease. J Clin Internal Med. 19:196–198. 2002.In Chinese.
9	Sun YP, Ma TY and Wu XR: Clinical analysis and mechanism of treatment of pregnancy-induced hypertension with Qingxintong. Practical J Obstet Gynecol. 7:141–143. 1991.In Chinese.
10	Huang YP and Ma TY: Treatment of intrauterine growth retardation with qingxintong. Chin J Obstet Gynecol. 28:333–336. 1993.In Chinese.
11	Wu XR, Li Y, Yang DS, Han BJ, Si YZ, Shan ZZ, Ma TY, Wen LZ, Sun YP and Huang YP: The utero-placental circulation, eugenics and the prevention and treatment of high risk pregnancies. J Tongji Med Univ. 14:1–7. 1994. View Article : Google Scholar : PubMed/NCBI
12	Huang YP, Ye DY, Wu P, Huang YF, Ying HG and Ma TY: The therapeutic effectiveness of inhaled DHAP in the treatment of intrauterine growth retardation. Acta Med Univ Sci Et Technol Huazhong. 31:192–194. 2002.In Chinese.
13	Wang Z, Gao HQ, An Y, Zhu GQ and Yang ZM: Effect of 3,4-dihydroxyacetophenone on rabbit platelet function. Zhongguo Yao Li Xue Bao. 5:187–192. 1984.In Chinese. PubMed/NCBI
14	Wang Z, Gao HQ, Zhu GQ, An Y and Huang RS: Effect of 3,4-dihydroxyacetophenone on the generation of PGI2-like substances in the rat aorta. Zhongguo Yao Li Xue Bao. 7:37–40. 1986.In Chinese. PubMed/NCBI
15	Xu H, Wang Z and An Y: Effect of 3,4-dihydroxyacetophenone on platelet phosphodiesterase in rabbits. Acta Pharmacol Sin. 8:159–162. 1986.In Chinese.
16	Wang Z, An Y, Liu Z, Zhu GQ and Huang RS: Effect of 3,4-dihy-droxyacetophenone on TXA2 release from rabbit platelets. Yao Xue Xue Bao. 22:330–334. 1987.In Chinese. PubMed/NCBI
17	Li S, Li Y, Xiong Z and Wu X: Influence of Qingxingtong on platelet function of PIH-patients. J Tongji Med Univ. 23:305–307. 1994.In Chinese.
18	Wang Z, Huang RS, Gao YH, An Y and Qiang ZG: 3,4-Dihy-droxyacetophenone-a cyclooxygenase inhibitor (brief). Acta Pharmacol Sin. 1:351988.In Chinese.
19	Shi L, Qin ZH and Gao SX: Effect of 3,4-dihydroxyacetophe-none on the membrane fluidity of platelets by fluorescence polarization analysis. Zhongguo Yao Li Xue Bao. 7:149–151. 1986.In Chinese. PubMed/NCBI
20	Shan Z, Chang C, Feng L and Wu X: The regulatory effect of 3,4-dihydroxyacetophenone on tPA and PAI activity of the vascular endothelial calls. Pharmacol Clin Chin Materia Med. 6:33–35. 1995.In Chinese.
21	Beijing Institute of Pharmaceutical Industry, The People's Liberation Army 157 Hospital: Pharmacological study of bald holly leaves on coronary heart disease. Chin Pharm J. 15:421980.In Chinese.
22	Wu P, Huang YP and Ye DJ: Advances in research on the mechanism of qingxintong promoting blood circulation and removing blood stasis. Chin Trad Herbal Drugs. 23:277–279. 2001.In Chinese.
23	Ullah F, Wang DX, Ming Z and Yu SB: Effects of 3,4-dihydroxy-acetophenone (3,4-DHAP) on hypoxic pulmonary and systemic vascular response in dogs. J Tongji Med Univ. 15:26–30. 1995. View Article : Google Scholar
24	Hong ZG, Wang DX, Jin S, Zhang J, Wang XL and Ye DY: Effect of 3,4-dihydroxyacetophenone on delayed rectifier potassium current of the intrapulmonary artery smooth muscle cells in rats. Chin Pharmacol Bull. 18:386–389. 2002.In Chinese.
25	Yang DS, Xi-rui W and Ting-yuan M: Effects of 3,4-dihy-droxyacetophenone on the biosynthesis of TXA2 and PGI2 in human placental villus and umbilical artery segments in vitro. Prostaglandins. 38:497–504. 1989. View Article : Google Scholar : PubMed/NCBI
26	Hang YP, Ye DJ and Ma TJ: Effect of Qingxintong on nitric oxide synthase and plasma endothelin in placental vascular wall of patients with pregnancy induced hypertension. Chin J Obstet Gynecol. 31:667–669. 1996.In Chinese.
27	Li G, Wu P, Zhang DJ, Ye DY and Li F: Mechanism of inhibition of 3, 4-dihydroxyacetophenone on LPS-induced apoptosis of RAW264.7 macrophages in mice. Chin Trad Herbal Drugs. 36:1835–1838. 2005.In Chinese.
28	Wu P, Zhang L, Zhou X, Li Y, Zhang D, Wan J and Ye D: Inflammation pro-resolving potential of 3,4-dihydroxyaceto-phenone through 15-deoxy-Δ12,14-prostaglandin J2 in murine macrophages. Int Immunopharmacol. 7:1450–1459. 2007. View Article : Google Scholar : PubMed/NCBI
29	Zhang D, Liu T, Liu J, Cui X, Guo J, Wang J and Ye D: Relationship between therapeutic and preventive effect of dihydroxyaceto-phenone in treating atherosclerosis and the Toll-like-receptor 4 pathway. Trad Chin Drug Res Clin Pharmacol. 20:404–407. 2009.In Chinese.
30	Zhang D, Liu T, Cui X, Liu J, Guo J, Wang J and Ye D: Preventive effect of 3,4-dihydroxyacetophenone on atherosclerosis and role of visfatin expression. Chin J Pathophysiol. 26:1700–1703. 2010.In Chinese.
31	Zhang D, Gong Y, Liu J, Wang J, Wang L and Liu T: Effects of 3,4-dihydroxyacetophenone on 5-lipoxygenase in macrophages of atherosclerosis plaque. Trad Chin Drug Res Clin Pharmacol. 23:243–246. 2012.In Chinese.
32	Zhang DJ, Liu JY, Wang L, Wang J, Li W, Zhuang B, Hou J and Liu T: Effects of 3,4-dihydroxyacetophenone on the hypercho-lesterolemia-induced atherosclerotic rabbits. Biol Pharm Bull. 36:733–740. 2013. View Article : Google Scholar
33	Li SX, Li Y, Shan ZZ, Xiong ZM, Wu XR and Yin XG: Pharmacokinetics of Qingxintong in rabbits. Acta Universitatis Medictnae Tangji. 22:91–93. 1993.In Chinese.
34	Pang X, Fu G and Zuo M: Comparison of bioavailability of Qingxintong by three administration routes. Trad Chin Drug Res Clin Pharmacol. 13:31–32. 2001.In Chinese.
35	Eun JK, Jong WA, Hye SL and Wolfram C: Determination of peripheral catecholO-methyltransferase (COMT) activity in vivo using (2-¹⁴C)-3′,4′-dihyroxyacetophenone. Arch Pharm Res. 14:290–294. 1991. View Article : Google Scholar
36	Montenegro L, Carbone C, Maniscalco C, Lambusta D, Nicolosi G, Ventura CA and Puglisi G: In vitro evaluation of quercetin-3-O acyl esters as topical prodrugs. Int J Pharm. 336:257–262. 2007. View Article : Google Scholar : PubMed/NCBI
37	Jin YY, Zhang JS, Zhang Y and Zhang YH: Studies on the intestinal adsorption of crocin in rats and determination of the partition coefficient. J Chin Pharm Univ. 35:247–257. 2004.In Chinese.
38	Fang L: Pharmaceutics. 8th edition. People's Medical Publishing House; Beijing: pp. 137–139. 2016, In Chinese.
39	Zhou X, Zhang X, Han S, Dou Y, Liu M, Zhang L, Guo J, Shi Q, Gong G, Wang R, et al: Yeast microcapsule-mediated targeted delivery of diverse nanoparticles for imaging and therapy via the oral route. Nano Lett. 17:1056–1064. 2017. View Article : Google Scholar : PubMed/NCBI
40	You QD: Medicinal Chemistry. 8th edition. People's Medical Publishing House; Beijing: pp. 462016, In Chinese.
41	Liu CX: Introduction to Pharmacokinetics. Liu D: China Academic Press Publication; Beijing: pp. 215–217. 1984, In Chinese.